Ng George K 4/A

What Happened George K. Ng, CEO of Processa Pharmaceuticals, purchased 1,843 shares on April 15, 2026 at $2.97 per share for a total of $5,474 (transaction code P — purchase, open-market or private). This reported purchase is a buy transaction rather than a sale.

Key Details

• Transaction date: April 15, 2026; Price: $2.97 per share; Total value: $5,474 (approx.).
• Report filed as an amendment on May 19, 2026 (the Form 4 is AMENDED).
• Transaction type: P = Purchase (open market or private purchase per filing).
• Shares owned after transaction: not specified in this amended filing.
• No footnotes such as 10b5-1 plan, tax withholding, or cashless exercise are disclosed in the amendment.
• Timeliness: the Apr 15 transaction was reported via an amended Form 4 on May 19, indicating the filing was not reported within the typical 2-business-day window.

Context This is a small-dollar insider purchase (about $5.5K), which can be interpreted simply as an insider acquisition but is limited in scale. The amended/late filing reduces near-term transparency for investors; however, the transaction itself is a straightforward purchase and not a derivative exercise, gift, or sale.